E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Type 2 Diabetes Patients with type 2 diabetes who have suboptimal glycaemic control (HbA1c >58mmol/mol, 58%) on one or two oral therapies, not including a thiazolidinedione, a DPP4 inhibitor or a SGLT2 inhibitor |
|
E.1.1.1 | Medical condition in easily understood language |
Type 2 Diabetes - patients who currently take one or two glucose-lowering tablets and whose blood glucose remains above 58mmol/mol (7.5%) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10067585 |
E.1.2 | Term | Type 2 diabetes mellitus |
E.1.2 | System Organ Class | 10027433 - Metabolism and nutrition disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
This study aims to test 2 hypotheses of how well or poorly different subgroups of patients respond to particular drugs based on particular clinical characteristics such as their weight or blood test results.
Hypothesis 1: Patients with insulin resistance (characterised by a raised BMI >30 kg/m2), compared to non-obese patients (BMI ≤30) will: a) respond well to pioglitazone b) respond less well to sitagliptin
Hypothesis 2: Patients with modestly reduced renal function, compared to those with normal renal function will: a) respond poorly to canagliflozin b) respond well to sitagliptin
Therefore the study’s primary research question: a) Do obese patients (BMI >30kgm-2), compared to non-obese patients, achieve a lower HbA1c when given pioglitazone rather than sitagliptin?
b) Do patients with an eGFR <90 mls/min/1.73m2 achieve a lower HbA1c, compared to patients with an eGFR>90 mls/min/1.73m2, when givena sitagliptin rather than canagliflozin.
|
|
E.2.2 | Secondary objectives of the trial |
The study's secondary research objectives are to look at:
a) Which treatment patients prefer, both within the different subgroups (BMI above/below 30 and reduced/normal renal function) and overall.
b) The number of side effects experienced, both within the different subgroups and for the different drugs. These will specifically include weight gain, hypoglycaemia, oedema, genital tract infection and discontinuation of therapy.
c) Whether there is a gender difference in response to pioglitazone therapy |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Clinical diagnosis of Type 2 diabetes • Age ≥30 and ≤80 • Currently treated with either metformin alone, or two classes of oral glucose-lowering therapy (given either as separate or combined medications), that do not include a DPP4-inhibitor, a SGLT2-inhibitor or a thiazolidinedione. • Diabetes duration ≥12months • No change in diabetes treatment (new treatments or dose change) within previous 3 months • HbA1c >58mmol/mol (7.5%) & ≤ 110mmol/mol (12.2%) – confirmed at screening visit • eGFR ≥ 60mls/min/1.73m² - confirmed at screening visit • Able and willing to give informed consent
|
|
E.4 | Principal exclusion criteria |
• Changes in glucose-lowering therapy or dose within last 3 months • HbA1c ≤ 58mmol/mol (7.5%) & >110mmol/mol (12.2%) • eGFR <60mls/min/1.73m². • Diabetes duration <12 months • ALT >2.5 x upper limit of the assay normal range or known liver disease, specifically >30 μmol/L that is associated with other evidence of liver failure. • Insulin treated within the last 12 months • Treatment with study dugs within the last 3 months • Limb ischaemia shown by absence of both pulses in one or both feet • Currently treated with corticosteroids • Active infection (any infection requiring antibiotics at present) • Active foot ulcer • Recent (within 3 months) significant surgery or planned surgery (excluding minor procedures) • Acute cardiovascular episode (angina, myocardial infarction, stroke, transient ischemic episode) occurring within the previous 3 months • History of heart failure or current use of loop diuretic therapy (Furosemide or Bumetanide) • History of bladder carcinoma or current/ongoing investigation for macroscopic haematuria • History of Diabetic Ketoacidosis or pancreatitis • Pregnant, breastfeeding or planning a pregnancy over the study period • Concurrent Participation on another Clinical Trial of an Investigational Medicinal Product • Unable or unwilling to give informed consent
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome of this crossover study is HbA1c on treatment after 16 weeks. When a subject withdraws from a treatment arm before 16 weeks an HbA1c will be taken and used if the subject has been taking the medication at least 8 weeks. If a subject has taken the medication for less than 8 weeks their HbA1c measure will not be used in primary analysis.
The HbA1c primary outcome measure will be that achieved after 16 weeks on therapy and not the percentage or absolute HbA1c change between either study or therapy baseline and end of treatment arm.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary outcome measurement will be taken at the end of each of the three 16 week on-treatment periods. |
|
E.5.2 | Secondary end point(s) |
At the end of the study, patient treatment preference will be recorded after feeding back to the patient for each of the 3 therapies their HbA1c, weight change, frequency of hypoglycaemias, any patient reported side effects and the patient’s verdict on each therapy and ask them which treatments they would take long term and the reason for their preference.
Frequency and severity of side effects will be recorded throughout the study. Participants that routinely self-monitor their blood glucose levels with devices issued by their clinician will be asked to record their glucose values immediately following hypoglycaemias. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary end points will be evaluated at the end of each of the three 16 week on-treatment periods. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 19 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS plus 6 months to enable follow-up |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 2 |
E.8.9.2 | In all countries concerned by the trial days | 31 |